Theravance Q4 2021 Earnings Report

Reported financial results for the fourth quarter and full year ended December 31, 2021.

Key Takeaways

Theravance Biopharma reported their Q4 and full year 2021 financial results. YUPELRI saw the highest quarter of net sales since its launch. GSK’s TRELEGY sales reached their highest levels since launch driven by growth in the asthma indication. The company expects to become sustainably cash-flow positive beginning the second half of this year.

YUPELRI saw the highest quarter of net sales since its launch.

GSK’s TRELEGY sales reached their highest levels since launch driven by growth in the asthma indication.

Strong performance by YUPELRI in Q4 and into 2022 will enable investment in the inhaled JAK inhibitor respiratory pipeline.

The company remains on target to become sustainably cash-flow positive beginning the second half of this year.

Total Revenue

$14.9M

Previous year: $18.7M

-20.2%

EPS

-$0.18

Previous year: -$0.92

-80.4%